Sugi Predict

Sugi Predict / Compounds / SCHEMBL7863751

SCHEMBL7863751

SCHEMBL7863751

O=[N+]([O-])c1ccc2c(c1)CC=C2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA9 Q16790 1/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ HIF1A Q16665 2/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ STAT3 P40763 1/20 0.45
▸ MTOR P42345 1/20 0.45
▸ PNMT P11086 5/20 0.44
▸ ADRA2A P08913 3/20 0.44
▸ LMNA P02545 2/20 0.44
▸ MAPT P10636 1/20 0.44
▸ TLR9 Q9NR96 1/20 0.44
▸ TSHR P16473 3/20 0.42
▸ TDP2 O95551 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ TDP1 Q9NUW8 3/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ ADRA2B P18089 2/20 0.41
▸ ADRA2C P18825 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17955411 0.86 TSHR (0.41) CA9MEN1RAB9AKMT2AHIF1A
SCHEMBL2728137 0.85 CA9 (0.49) CA9MEN1RAB9AKMT2AHIF1A
SCHEMBL1779718 0.82 PNMT (0.45) CA9MEN1RAB9AKMT2AHIF1A
SCHEMBL7539847 0.79 PNMT (0.51) CA9MEN1RAB9AKMT2APNMT
SCHEMBL8893107 0.77 PTPRC (0.49) CA9MEN1RAB9AKMT2AHIF1A
SCHEMBL12797258 0.75 MEN1 (0.43) CA9MEN1RAB9AKMT2ANPC1
SCHEMBL29989303 0.75 HSPB1 (0.47) MEN1RAB9AKMT2ANPC1LMNA
SCHEMBL9256419 0.74 PNMT (0.47) MEN1RAB9AKMT2AHIF1ANPC1
SCHEMBL3442079 0.71 CA9 (0.47) CA9MEN1RAB9AKMT2AHIF1A
SCHEMBL8471105 0.71 PNMT (0.45) MEN1RAB9AKMT2APNMTADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441679-B2 Acrylamide-substituted indane compounds and therapeutic use thereof SANOFI (FR) 2025-10-14 — — US disclosed
CN-116057042-B Acrylamide-substituted indane compounds and their therapeutic uses 赛诺菲 2024-10-18 — — CN disclosed
US-20230265047-A1 Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof SANOFI (FR) 2023-08-24 — — US disclosed
US-20230265047-A1 Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof SANOFI (FR) 2023-08-24 — — US disclosed
EP-4188907-A1 ACRYLAMIDE-SUBSTITUTED INDANE COMPOUNDS AND THERAPEUTIC USE THEREOF SANOFI (FR) 2023-06-07 — — EP disclosed
CN-116057042-A Acrylamide-substituted indane compounds and their therapeutic uses 赛诺菲 2023-05-02 — — CN disclosed
CN-114127638-A Negative photosensitive resin composition, cured film, organic EL display, and method for producing cured film 东丽株式会社 2022-03-01 — — CN disclosed
WO-2022023460-A1 ACRYLAMIDE-SUBSTITUTED INDANE COMPOUNDS AND THERAPEUTIC USE THEREOF SANOFI (FR) 2022-02-03 — — WO disclosed
US-10954178-B1 Synthesis of haloindenes THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2021-03-23 — — US disclosed
US-9624215-B2 Amine derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2017-04-18 — — US disclosed
US-20150299189-A1 NOVEL AMINE DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2015-10-22 — — US disclosed
US-9156827-B2 Anticancer agent THE UNIVERSITY OF TOKYO (JP) 2015-10-13 — — US disclosed
US-20140349989-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF ALZHEIMER'S INSTITUTE OF AMERICA (US) 2014-11-27 — — US disclosed
US-20130102776-A1 ANTICANCER AGENT RIKEN (JP) 2013-04-25 — — US disclosed
US-20120288501-A1 SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) 2012-11-15 — — US disclosed
EP-1067932-A4 METHODS FOR INHIBITING MRP1 LILLY CO ELI (US) 2001-11-14 — — EP disclosed
CN-1296410-A Methods for inhibiting MRP1 LILLY CO ELI (US) 2001-05-23 — — CN disclosed
US-6221876-B1 190 KDA MULTIDRUG RESISTANCE PROTEIN (MRP1); 1-AMINO-2-HYDROXYINDAN-6-YL)ISOXAZOLO(3, 4-C)-1,2-DIHYDRO-3-METHYL-6-CHLOROQUINOLIN-2-ONE DERIVATIVES ELI LILLY AND COMPANY 2001-04-24 — — US disclosed
EP-1067932-A1 METHODS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2001-01-17 — — EP disclosed
WO-1999051236-A1 METHODS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 1999-10-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441679-B2 Acrylamide-substituted indane compounds and therapeutic use thereof IDH2, INA, IDH3A CA9 2729/4885MEN1 2972/4885RAB9A 4379/4885
US-20120288501-A1 SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE BRAF, RAF1, ARAF CA9 2324/4885MEN1 1815/4885RAB9A 1662/4885
US-20140349989-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF NFATC1, CD4, CD47 CA9 855/4885MEN1 4255/4885RAB9A 2221/4885
US-20150299189-A1 NOVEL AMINE DERIVATIVE OR SALT THEREOF HRH4, CLIC4, KRT18 CA9 2165/4885MEN1 3900/4885RAB9A 3312/4885
US-20130102776-A1 ANTICANCER AGENT PIM1, PIM3, PIM2 CA9 2721/4885MEN1 2639/4885RAB9A 1993/4885
US-20230265047-A1 Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof IDH2, INA, IDH3A CA9 2729/4885MEN1 2972/4885RAB9A 4379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.